Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:48 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer
NCT04188119 · The Christie NHS Foundation Trust · PHASE2 · withdrawn · last registry update 2025-12-08 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Unable to open” | Open Targets' class: uncategorised | Registry record, The Christie NHS Foundation Trust |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD274 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-25Results posted on the registry: AstraZeneca, Neoadjuvant Olaparib monotherapy group + Neoadjuvant combination therapy with olaparib plus durvalumab (NCT05498155)
- 2026-07-01Phase 3 first posted: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Trastuzumab Rezetecan for Injection + Adebrelimab Injection (NCT07679360)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision